CN101291678B - 核酸转运用载体组合物 - Google Patents

核酸转运用载体组合物 Download PDF

Info

Publication number
CN101291678B
CN101291678B CN2006800389545A CN200680038954A CN101291678B CN 101291678 B CN101291678 B CN 101291678B CN 2006800389545 A CN2006800389545 A CN 2006800389545A CN 200680038954 A CN200680038954 A CN 200680038954A CN 101291678 B CN101291678 B CN 101291678B
Authority
CN
China
Prior art keywords
nucleic acid
composition
component
acid delivery
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800389545A
Other languages
English (en)
Chinese (zh)
Other versions
CN101291678A (zh
Inventor
丰福秀一
宫尾英男
佐藤正子
关口和生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN101291678A publication Critical patent/CN101291678A/zh
Application granted granted Critical
Publication of CN101291678B publication Critical patent/CN101291678B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2006800389545A 2005-10-18 2006-10-17 核酸转运用载体组合物 Expired - Fee Related CN101291678B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP303497/2005 2005-10-18
JP2005303497 2005-10-18
PCT/JP2006/320617 WO2007046356A1 (ja) 2005-10-18 2006-10-17 核酸送達用キャリアー組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110461144.3A Division CN102512689B (zh) 2005-10-18 2006-10-17 核酸转运用载体组合物

Publications (2)

Publication Number Publication Date
CN101291678A CN101291678A (zh) 2008-10-22
CN101291678B true CN101291678B (zh) 2012-03-28

Family

ID=37962449

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800389545A Expired - Fee Related CN101291678B (zh) 2005-10-18 2006-10-17 核酸转运用载体组合物
CN201110461144.3A Expired - Fee Related CN102512689B (zh) 2005-10-18 2006-10-17 核酸转运用载体组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110461144.3A Expired - Fee Related CN102512689B (zh) 2005-10-18 2006-10-17 核酸转运用载体组合物

Country Status (19)

Country Link
US (1) US8030075B2 (https=)
EP (1) EP1946761B8 (https=)
JP (1) JP5046952B2 (https=)
KR (1) KR101324065B1 (https=)
CN (2) CN101291678B (https=)
AR (1) AR057553A1 (https=)
AU (1) AU2006305318B2 (https=)
BR (1) BRPI0617449A2 (https=)
CA (1) CA2624840A1 (https=)
CY (1) CY1114586T1 (https=)
DK (1) DK1946761T3 (https=)
ES (1) ES2412029T3 (https=)
MY (1) MY149502A (https=)
PL (1) PL1946761T3 (https=)
PT (1) PT1946761E (https=)
RU (1) RU2421227C2 (https=)
SI (1) SI1946761T1 (https=)
TW (1) TW200800235A (https=)
WO (1) WO2007046356A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512689A (zh) * 2005-10-18 2012-06-27 大塚制药株式会社 核酸转运用载体组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011114678A1 (ja) * 2010-03-15 2011-09-22 国立大学法人山口大学 哺乳動物細胞への遺伝子導入効率の向上剤
US9750819B2 (en) * 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
US9833416B2 (en) * 2014-04-04 2017-12-05 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
EP3329011B1 (en) * 2015-07-30 2019-12-18 Arcis Biotechnology Holdings Limited Method and composition
CN117481114A (zh) * 2023-10-27 2024-02-02 硅羿科技（上海）有限公司 纳米核酸农药、其制备方法和应用、以及核酸递送系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031132A1 (en) * 1997-12-12 1999-06-24 The University Of Queensland NOVEL SURFACE PROTEIN OF $i(NEISSERIA MENINGITIDIS)
WO2000027795A1 (en) * 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
WO2004004758A1 (en) * 2002-07-05 2004-01-15 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
WO2004033620A2 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
HUP9902217A3 (en) * 1999-06-29 2002-07-29 Szegoe Peter Polycation based bioconjugates and process for producing thereof
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
AU2005310131A1 (en) * 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched HK peptides as effective carriers of siRNA
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031132A1 (en) * 1997-12-12 1999-06-24 The University Of Queensland NOVEL SURFACE PROTEIN OF $i(NEISSERIA MENINGITIDIS)
WO2000027795A1 (en) * 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
WO2004033620A2 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
WO2004004758A1 (en) * 2002-07-05 2004-01-15 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hassan Farhood et al.The role of dioleoyl phosphatidylethanolamine in cationicliposome mediated gene transfer.Biochimica et Biophysica Acta1235 2.1995,1235(2),289-295. *
Wen-Chi Tseng et al.Liposome-based gene therapy.Pharmaceutical Science & Technology Today1 5.1998,1(5),206-213. *
付爱玲等.膜穿透肽介导的核酸转运.生命的化学23 5.2003,23(5),329-332. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512689A (zh) * 2005-10-18 2012-06-27 大塚制药株式会社 核酸转运用载体组合物

Also Published As

Publication number Publication date
WO2007046356A1 (ja) 2007-04-26
EP1946761A1 (en) 2008-07-23
EP1946761A4 (en) 2012-01-25
CN101291678A (zh) 2008-10-22
CY1114586T1 (el) 2016-10-05
DK1946761T3 (da) 2013-04-15
US8030075B2 (en) 2011-10-04
RU2421227C2 (ru) 2011-06-20
EP1946761B1 (en) 2013-04-03
US20090258923A1 (en) 2009-10-15
MY149502A (en) 2013-09-13
KR20080059648A (ko) 2008-06-30
CA2624840A1 (en) 2007-04-26
JP5046952B2 (ja) 2012-10-10
AU2006305318A1 (en) 2007-04-26
CN102512689A (zh) 2012-06-27
PL1946761T3 (pl) 2013-08-30
SI1946761T1 (sl) 2013-06-28
EP1946761B8 (en) 2013-05-22
KR101324065B1 (ko) 2013-10-31
ES2412029T3 (es) 2013-07-09
PT1946761E (pt) 2013-05-27
AR057553A1 (es) 2007-12-05
TWI376225B (https=) 2012-11-11
RU2008119498A (ru) 2009-11-27
JPWO2007046356A1 (ja) 2009-04-23
AU2006305318B2 (en) 2011-08-25
HK1119956A1 (en) 2009-03-20
CN102512689B (zh) 2014-08-20
TW200800235A (en) 2008-01-01
BRPI0617449A2 (pt) 2011-07-26
HK1171689A1 (en) 2013-04-05

Similar Documents

Publication Publication Date Title
ES2614115T3 (es) Sistema de micelas inversas que comprenden ácidos nucleicos y su uso
CN101646443B (zh) 速效型核酸转运用载体组合物
CN101291678B (zh) 核酸转运用载体组合物
AU2008325504B2 (en) Nucleic acid complex and nucleic acid delivery composition
HK1119956B (en) Carrier composition for nucleic acid transport
HK1171689B (en) Carrier composition for nucleic acid transport
CN102369282A (zh) 核酸复合体及核酸转运用组合物
HK1139041B (en) Prompt nucleic acid delivery carrier composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119956

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1119956

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120328

Termination date: 20161017